Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers," said Henry Li, PhD, chief scientific officer at CrownBio. "This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments."
"Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data," said Sheng Guo, PhD, head of bioinformatics at CrownBio. "These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
· https://www.crownbio.com · https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210110005013/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, 대한민국 국가유산과 함께하는 ‘갤럭시 AI’ 체험 프로그램 운영 - 뉴스와이어
- 유럽, 2050년까지 지속 가능한 도시 모빌리티 구축 위해 1조5000억유로가 필요 - 뉴스와이어
- Cloudera, 신규 파트너들과 손잡고 업계를 선도하는 ‘Enterprise AI Ecosystem’ 연합체 더욱 확장 - 뉴스
- 벤틀리시스템즈, 생성형 AI 발표… 토목 현장 설계의 게임 체인저 - 뉴스와이어
- 100년 만에 에베레스트산에서 영국 탐험가 앤드류 ‘샌디’ 어바인의 유해 일부 발견 추정 - 뉴스
- 지자체 혁신평가위, 2025 WFPL 8대 지자체 혁신평가 결과 내년 2월 발표 - 뉴스와이어
- Curia, 과학 기반 목표 이니셔티브 넷제로 표준 준수 약속 - 뉴스와이어
- Duck Creek Technologies, 종합적인 리스크 관리 및 완화 솔루션 제공 위해 ‘Risk Control Technologies’ 인수
- 에이지 오브 엠파이어 모바일, 홍보모델로 배우 최수종 발탁 - 뉴스와이어
- 벤틀리시스템즈, 인프라 엔지니어링 발전을 위한 개방형 데이터 생태계 공개 - 뉴스와이어